Four families! Fuhong, Hanlin, Adamu and MAb are listed on the market

On April 24, according to the announcement of Fosun Pharmaceutical and the CPM database, the listing application of adamumumab biological similar drugs of Fuhong Hanlin, its holding subsidiary, was accepted by nmpa (acceptance No.: cxss1900001) It is mainly suitable for the treatment of plaque psoriasis and rheumatoid arthritis Adamumumab really said not to mention that its R & D heat is comparable to PD-1 / L1 Up to now, sumac has been approved to nearly 20 indications worldwide, and it is still expanding In November 2011, nmpa approved adalimumab for the first time in the treatment of rheumatoid arthritis At present, it has been approved three indications in China: rheumatoid arthritis, ankylosing spondylitis and psoriasis In December 2015 and April 2017, nmpa approved the clinical trial of Fuhong Hanlin adalimumab in the treatment of indications of rheumatoid arthritis and plaque psoriasis Up to now, the indications for the treatment of plaque psoriasis are still in clinical stage III in China According to the announcement, as of December 2018, nearly 200 million yuan has been invested in the research and development of plaque psoriasis and rheumatoid arthritis indications for the biological analogues Up to now, the local enterprises that have applied for the listing of adamumumab biological similar drugs include BioTek, Haizheng pharmaceutical, and Xinda pharmaceutical Together with today's Fuhong Hanlin, it seems that they have gathered a good table According to the new drug development monitoring database (CPM), from the perspective of application progress, baiaotai is faster than Haizheng and Haizheng is faster than Xinda Last year was xiumeile's "year of water inversion" Four competitors emerged On October 16, amgevita and hyrimoz of amjin were officially sold in the EU and the UK respectively On October 17, imraldi of Samsung bioepis also announced its official sale in the EU So far, Mylan has not disclosed the specific listing time, but it is expected to launch in the near future The earliest sales time in the U.S market is January 31, 2023 In the face of so many competitors, even if it is better than Adamu mAb, it has to make price adjustment Rick Gonzalez, chief executive of Aberdeen, has said he expects a 10-80% price cut in the future In China, there are four teams that are covetous, but the sales volume of Sumeria music in China is not optimistic According to PDB, its market size has been shrinking since 2013, with a compound decline of more than 10% Data source: PDB thought that when drug K entered China that year, it was directly reduced to half of the price in the United States, and the listing of trepril mAb further sealed the price of this kind of drug at 1 / 3 of that of imported drugs So, how will xiumeile be considered in China?